Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 12/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22442223 | 0.81 | PARP1 (0.46) | ALOX5PARP1 | |
| SCHEMBL22442230 | 0.79 | PARP1 (0.42) | PARP1 | |
| SCHEMBL22367385 | 0.79 | PARP1 (0.42) | ALOX5PARP1HTR2AHTR2CHTR2B | |
| SCHEMBL22442238 | 0.77 | PARP1 (0.40) | PARP1SLC6A2CACNA2D1 | |
| SCHEMBL22367322 | 0.76 | PARP10 (0.40) | PARP1SLC6A2CACNA2D1TNKSTNKS2 | |
| SCHEMBL19564595 | 0.76 | PRKD1 (0.40) | PARP1SLC6A2CACNA2D1HTR2A | |
| SCHEMBL22367368 | 0.74 | CACNA2D1 (0.40) | PARP1SLC6A2CACNA2D1 | |
| SCHEMBL22367242 | 0.73 | PARP1 (0.46) | PARP1TNKS2 | |
| SCHEMBL10008159 | 0.73 | GRM5 (0.53) | ALOX5PARP1GRM5 | |
| SCHEMBL23778811 | 0.70 | PARP1 (0.36) | ALOX5PARP1SLC6A2CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-08-02 | — | — | US | disclosed |
| EP-3700890-B1 | ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS SA (ES) | 2021-11-17 | — | — | EP | disclosed |
| EP-3700890-B1 | ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS SA (ES) | 2021-11-17 | — | — | EP | disclosed |
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-24 | — | — | US | disclosed |
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-24 | — | — | US | disclosed |
| EP-3700890-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299297-A1 | NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | CACNA1B, CACNB2, CACNA1G | ALOX5 1027/4885PARP1 2628/4885BRD9 4035/4885 |
| US-11401270-B2 | Alcoxyamino derivatives for treating pain and pain related conditions | CACNA1B, CACNA1G, CACNA2D2 | ALOX5 1107/4885PARP1 2206/4885BRD9 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.